

ACVR1/JAK1/JAK2 Inhibitor Momelotinib Reverses Transfusion Dependency and Suppresses Hepcidin in Myelofibrosis Ph2 Trial

S Oh, et al


Supplemental Data

Figure Legend


Supplemental Figure 1. Erythropoiesis activity in TI-R and TI-NR subgroups. Changes in biomarker levels in the TI-NR and TI-R subgroups in up to 24 weeks of treatment: reticulocytes (A), erythropoietin (B), transferrin saturation (C), and ferritin (D).

TI-NR transfusion-independent non-responders; TI-R, transfusion-independent responders.


Supplemental Figure1A




Supplemental Figure1B



Supplemental Figure1C



Supplemental Figure1D



Supplemental Table 1. Median (interquartile range) values and change in biomarkers.

Biomarker		BL	Week 24	Δ from BL	% Δ from BL
LIC, mg/g	TI-R	2.4 (1.6, 4.0)	3.2 (1.8, 4.9)	0.2 (-0.2, 0.9)	4.7 (-18.4, 25.0)
	TI-NR	4.2 (2.6, 11.3)	6.9 (5.6, 12.1)	2.3 (0.5, 3.5)	53.3 (20.6, 86.2)
Ferritin, ng/mL	TI-R	605.9 (372.7, 1018.5)	635.0 (136.4, 1269.1)	-30.7 (-231.3, 35.5)	-14.2 (-40.2, 6.6)
	TI-NR	1259.4 (441.6, 2321.5)	1443.4 (937.5, 2908.0)	218.8 (-100.4, 934.7)	15.4 (-20.7, 59.7)

BL, baseline; Δ, change; LIC, liver iron content; TI-NR transfusion-independent non-responders; TI-R, transfusion-independent responders.

Supplemental Table 2. Median (interquartile range) values for phosphorylated STAT3/total STAT3 ratio pre-dose and percent change at 2, 4, and 6 hours post-dose at first dose and at steady state.

Timepoint		Pre-dose	Δ2 hr post-dose	Δ4 hr post-dose	Δ6 hr post-dose
Enrollment	TI-R	0.9 (0.9, 1.0)	-13.2 (-38.9, -11.5)	-9.6 (-23.2, -0.5)	-9.1 (-17.2, -5.7)
	TI-NR	0.8 (0.6, 1.0)	-15.5 (-23.2, 2.5)	-9.7 (-28.0, -2.3)	-3.7 (-12.1, 3.7)
Week 4	TI-R	0.9 (0.8, 1.0)	-14.3 (-17.5, 20.3)	3.0 (-32.9, 118.3)	12.5 (-29.4, 56.0)
	TI-NR	0.9 (0.9, 1.0)	-9.1 (-22.6, 9.6)	-13.4 (-23.7, 23.9)	-6.1 (-17.1, 32.8)

BL, baseline; Δ, change; pSTAT3, phosphorylated signal transducer and activator of transcription 3; TI-NR transfusion-independent non-responders; TI-R, transfusion-independent responders.